In 2023, Slovakia led global anxiolytic sales per capita, with $2.5 USD, followed by the Czech Republic at $1.7. Australia's decrease of 2.82% contrasts with Slovakia's 9.34% surge. Estonia, Germany, and Italy remained stable, while Chile dropped 4.71%. Notably, Slovakia's growth showcases increased anxiolytic demand, while Italy's low value reflects limited use or access.
Future Trends to Watch:
- Potential growth in Eastern Europe's anxiolytic market, notably Slovakia.
- Australia and Chile may face challenges sustaining current levels.
- Economic factors impacting medicine affordability could influence international sales dynamics.
Top countries in Anxiolytic Medicine Sales by Country
| # | 8 Countries | US Dollars Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Slovakia | 2.5 | 2023 | +8.7% | +9.34% | View data |
| 2 | 2 Czech Republic | 1.7 | 2023 | +13.33% | 0% | View data |
| 3 | 3 Australia | 1.3 | 2023 | 0% | -2.82% | View data |
| 4 | 4 Estonia | 1.3 | 2023 | 0% | +1.61% | View data |
| 5 | 5 South Korea | 1.1 | 2023 | 0% | 0% | View data |
| 6 | 6 Chile | 1.1 | 2023 | +10% | -4.71% | View data |
| 7 | 7 Germany | 0.9 | 2023 | 0% | 0% | View data |
| 8 | 8 Italy | 0.1 | 2023 | 0% | 0% | View data |
